


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:32Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406256" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406256</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="c6491414" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">mp</journal-id><journal-title-group><journal-title>Molecular Pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><self-uri>pubs.acs.org/molecularpharmaceutics</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406256</article-id><article-id pub-id-type="pmcid-ver">PMC12406256.1</article-id><article-id pub-id-type="pmcaid">12406256</article-id><article-id pub-id-type="pmcaiid">12406256</article-id><article-id pub-id-type="pmid">40773056</article-id><article-id pub-id-type="doi">10.1021/acs.molpharmaceut.5c00705</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Food Additives
Inhibit Intestinal Drug Transporters
but Have Limited Effect on In Vitro Drug Permeability</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e19-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7272847</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1163-0182</contrib-id><name name-style="western"><surname>Suominen</surname><given-names initials="L">Laura</given-names></name></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7470713</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-9964-6540</contrib-id><name name-style="western"><surname>Stenberg</surname><given-names initials="E">Emilia</given-names></name></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3094456</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6960-7757</contrib-id><name name-style="western"><surname>Sj&#246;stedt</surname><given-names initials="N">Noora</given-names></name></contrib><contrib id="ath4" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1144908</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6427-8042</contrib-id><name name-style="western"><surname>Kidron</surname><given-names initials="H">Heidi</given-names></name><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1">
<institution content-type="dept">Drug Research Program, Division
of Pharmaceutical Biosciences, Faculty of Pharmacy</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">3835</institution-id><institution>University of Helsinki</institution></institution-wrap>, <city>Helsinki</city>
<postal-code>FI-00014</postal-code>, <country country="FI">Finland</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>heidi.kidron@helsinki.fi</email>. Tel.: <phone>+358294159518</phone>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>01</day><month>9</month><year>2025</year></pub-date><volume>22</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>5627</fpage><lpage>5637</lpage><history><date date-type="received"><day>15</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>7</month><year>2025</year></date><date date-type="online"><day>07</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-07"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-07">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="mp5c00705.pdf"/><abstract><p>Food additives are
chemical substances that are added
to processed
food to improve its flavor, texture, or appearance. Food additives
can inhibit intestinal transporters, such as breast cancer resistance
protein (BCRP), multidrug resistance associated protein 2 (MRP2),
organic anion transporting polypeptide 2B1 (OATP2B1), and P-glycoprotein
(P-gp). This inhibition could potentially affect the absorption of
their substrate drugs and cause unwanted food&#8211;drug interactions.
In this study, 22 food additives were evaluated for their impact on
BCRP, MRP2, OATP2B1, and P-gp transport. The inhibition potency toward
intestinal transporters was first studied using membrane vesicles
and HEK293 cells. In these assays, four food additives (beta-carotene,
butylated hydroxytoluene, dodecyl gallate, and octyl gallate) were
identified as inhibitors. Seven food additives (allura red AC, beta-carotene,
brilliant blue FCF, carmoisine, neohesperidin DC, sunset yellow FCF,
and tartrazine), which were identified as inhibitors either in the
current study or in our previous studies, were selected for Caco-2
permeability studies to further evaluate their possible effect on
drug absorption. None of the selected food additives showed any effect
on sulfasalazine permeability. These results suggest that the selected
food additives are inhibitors of the studied transporters but are
unlikely to cause clinically significant intestinal transporter-mediated
drug interactions.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="mp5c00705_0006.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="mp5c00705_0004.jpg"/></abstract><kwd-group><kwd>drug transporters</kwd><kwd>beta-carotene</kwd><kwd>sulfasalazine</kwd><kwd>Caco-2</kwd><kwd>food&#8722;drug interaction</kwd></kwd-group><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Research Council of Finland</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100002341</institution-id></institution-wrap></funding-source><award-id>332949</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Svenska Kulturfonden</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100007247</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>Doctoral Education Pilot in Precision Cancer Medicine</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">NA</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group id="fnd-4"><funding-source><institution-wrap><institution>GeneCellNano Flagship</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">NA</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mp5c00705</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mp5c00705</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>a3459ec82f0dbba10b06a7220e9fd74fdf7b4349ef8d149b75ab6ef218e861d4</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>The use of additives in
processed food has increased during the
recent decades, as ultraprocessed foods, which typically contain various
additives, have come to predominate diets globally.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>&#8722;<xref rid="ref2" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref3" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref4" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr"/>
</named-content> Food additives are used to generate or improve desirable properties
of food products, such as flavor, color, or texture. In the European
Union (EU), over 300 substances are approved for use as food additives.<xref rid="ref7" ref-type="bibr"/> Furthermore, some food additives (e.g., antioxidants)
are used as pharmaceutical excipients in drug products. Pharmaceutical
excipients, e.g., Tween 20, Tween 80, and PEG 400, can interact with
intestinal drug transporters even though they are considered pharmacologically
inactive.<named-content content-type="bibref-group">
<xref rid="ref8" ref-type="bibr"/>&#8722;<xref rid="ref9" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref10" ref-type="bibr"/>
</named-content> The European Food Safety Authority (EFSA) assesses
the safety of food additives before they are allowed in food products
in the EU, but possible metabolizing enzyme- or transporter-mediated
drug interactions are rarely evaluated. We have previously studied
the influence of food additives on intestinal drug transporters breast
cancer resistance protein (BCRP), multidrug resistance-associated
protein 2 (MRP2), organic anion transporting polypeptide 2B1 (OATP2B1),
and P-glycoprotein (P-gp) in vitro. In these studies, we identified
inhibitors among colorants and sweeteners.<named-content content-type="bibref-group">
<xref rid="ref11" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/>
</named-content> Others have identified transporter inhibitors among drug excipients,
such as antioxidants, flavoring agents, emulsifiers, and colorants,
that are also used as food additives.<named-content content-type="bibref-group">
<xref rid="ref13" ref-type="bibr"/>&#8722;<xref rid="ref14" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref17" ref-type="bibr"/>
</named-content>
</p><p>The studied transporters (BCRP, MRP2, OATP2B1,
and P-gp) are important
for drug absorption in the intestine since they transport a wide range
of drugs through the membranes of enterocytes.<xref rid="ref18" ref-type="bibr"/> P-gp, BCRP, and MRP2 belong to the family of ATP-binding
cassette (ABC) transporters and are expressed in the apical membrane
of enterocytes.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>&#8722;<xref rid="ref20" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref21" ref-type="bibr"/>
</named-content> Their role in enterocytes is to efflux drugs back
into the gut lumen, preventing absorption. On the other hand, OATP2B1,
a member of the solute carrier (SLC) transporter family, facilitates
drug uptake into enterocytes where it may be expressed in both apical
and basolateral membranes, although its exact localization remains
uncertain.<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>,<xref rid="ref23" ref-type="bibr"/>
</named-content> The interference of transporter
function in the small intestine can therefore impact drug absorption
and bioavailability. This transport modulation can lead to complex
drug&#8211;drug interactions (DDIs) and food&#8211;drug interactions
(FDIs), which are critical considerations in both clinical and dietary
contexts. Regulatory agencies, such as the U.S. Food and Drug Administration
(FDA) and the European Medicines Agency (EMA), recommend comprehensive
studies to identify potential DDIs that could affect drug safety and
efficacy as part of the drug approval process. Evaluating BCRP- and
P-gp-mediated interactions is recommended, and if needed, MRP2 and
OATP2B1 can be included in these studies.<xref rid="ref24" ref-type="bibr"/>
</p><p>Studying FDIs is necessary because these interactions can
be clinically
significant. One of the most well-known causes of FDIs is grapefruit
juice. Grapefruit juice inhibits cytochrome P450 3A4 (CYP3A4), which
is the most abundant intestinal CYP enzyme.<named-content content-type="bibref-group">
<xref rid="ref25" ref-type="bibr"/>&#8722;<xref rid="ref26" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref27" ref-type="bibr"/>
</named-content> Thus, the bioavailability
of drugs that are substrates of CYP3A4 increases.<named-content content-type="bibref-group">
<xref rid="ref28" ref-type="bibr"/>&#8722;<xref rid="ref29" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref30" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref31" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref32" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref33" ref-type="bibr"/>
</named-content> Grapefruit juice also inhibits the function of OATPs, and additionally,
other fruit juices, such as apple and orange juice, and green tea
have been found to inhibit OATPs.<named-content content-type="bibref-group">
<xref rid="ref34" ref-type="bibr"/>&#8722;<xref rid="ref35" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref36" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref37" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref38" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref39" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref40" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref41" ref-type="bibr"/>
</named-content> Consequently, studies should be focused not only on the inherent
toxicity of food constituents but also on how they affect the disposition
of endogenous compounds or xenobiotics. Moreover, unidentified FDIs
may explain some of the observed interindividual variability in drug
exposure.</p><p>Previous studies by us and others have shown that
food additives
may disturb the function of intestinal transporters. Therefore, we
tested 22 additional food additives, which included sweeteners, colorants,
and antioxidants. We further examined how inhibitors identified here
and in our previous studies could affect drug absorption by testing
their impact on the permeability of sulfasalazine, a recommended substrate
for BCRP,<xref rid="ref24" ref-type="bibr"/> in Caco-2 cells.</p></sec><sec id="sec2"><label>2</label><title>Materials and Methods</title><sec id="sec2.1"><label>2.1</label><title>Materials</title><p>Unless
otherwise stated,
the food additives were purchased from Sigma-Aldrich (St. Louis, MO)
and dissolved in dimethyl sulfoxide (DMSO) at 10&#8211;100 mM. Transporter
substrates Lucifer yellow (LY), sulfasalazine, 5-carboxyfluorescein
(5-CF), and 5(6)-carboxy-2,7-dichlorofluorescein (CDCF) were purchased
from Sigma-Aldrich. <italic toggle="yes">N</italic>-methyl-quinidine (NMQ) was
purchased from Solvo Biotechnology (Szeged, Hungary). Transporter
inhibitors benzbromarone, Ko-143, and verapamil as well as all other
reagents were from Sigma-Aldrich if not otherwise specified. All water
used was Milli-Q water. Human embryonic kidney (HEK293) and Caco-2
cells were from the American Type Culture Collection (ATCC). Dulbecco&#8217;s
modified Eagle&#8217;s medium (DMEM; cat. 32430027 for HEK293 cells
and cat. 41965039 for Caco-2 cells), MEM nonessential amino acids,
penicillin&#8211;streptomycin, and fetal bovine serum (FBS) were
obtained from Thermo Fisher Scientific (Waltham, MA).</p></sec><sec id="sec2.2"><label>2.2</label><title>Vesicular Transport Assay</title><p>Transport
inhibition by 22 food additives was tested with <italic toggle="yes">Spodoptera
frugiperda</italic> (Sf9) derived crude membrane vesicles expressing
BCRP, MRP2, or P-gp produced in-house. The assays were carried out
as previously described in Sj&#246;stedt et al.<xref rid="ref11" ref-type="bibr"/> using fluorescent substrates, DMSO as a negative control,
and positive control inhibitors in 96-well plates (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Vesicles (50 &#956;g total
protein/well) were diluted in an assay buffer (40 mM MOPS&#8211;Tris
pH 7.0, 60 mM KCl, and 6 mM MgCl<sub>2</sub>) with the substrate,
and food additives (final concentration of 50 &#956;M) in DMSO were
added to the mixture. After preincubation, either the assay buffer
or Mg-ATP solution (final concentration 4 mM) was added to the plate
to start the reaction. The plate was incubated at 37 &#176;C, and
the reaction was stopped with an ice-cold washing mixture (40 mM MOPS-Tris
pH 7.0 and 70 mM KCl). Samples were moved to a MultiScreenHTS-FB Plate
Glass fiber 1.0 &#956;m/0.65 &#956;m Durapore filter plate (Millipore,
USA), and the wells were washed five times with the ice-cold washing
mixture. For BCRP and MRP2, the fluorescent substrate was eluted from
the filters with 100 &#956;L 0.1 M NaOH. For LY samples, an equal
volume of 0.1 M HCl was added to neutralize the samples before fluorescence
measurement. The amount of the substrate accumulated into the vesicles
was measured by fluorescent detection using a Varioskan LUX microplate
reader (Thermo Fisher Scientific, Finland) (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). The accumulation into the P-gp vesicles
was measured with high-performance liquid chromatography (HPLC) (Agilent
110 series, Agilent Technologies, USA) after lysis and elution of
the vesicle contents with 100 &#956;L 3:1 methanol/water + 0.1% formic
acid. The column used was a Poroshell 120 EC-C18 with a size of 4.6
&#215; 100 mm and 2.7 &#956;m particle size. Eluent A was 0.1% formic
acid, and eluent B was acetonitrile. The flow rate of eluent was 1
mL/min, and the injection volume of samples was 10 &#956;L. The following
method was used for analysis: 0&#8211;1 min (15% B), 1&#8211;3 min
(15&#8211;35% B), 3&#8211;4 min (90% B), and 4&#8211;6.5 min (15%
B). The retention time for NMQ was around 2.5 min.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Assay Conditions Used in the Inhibition
Studies<xref rid="t1fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">substrate</th><th align="center" colspan="1" rowspan="1">positive control</th><th align="center" colspan="1" rowspan="1">preincubation
time</th><th align="center" colspan="1" rowspan="1">incubation time</th><th align="center" colspan="1" rowspan="1">elution solution</th><th align="center" colspan="1" rowspan="1">fluorescence
wavelengths</th></tr></thead><tbody><tr><td rowspan="2" align="left" colspan="1">BCRP</td><td rowspan="2" align="left" colspan="1">LY 50&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">sulfasalazine 50&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">10&#160;min</td><td rowspan="2" align="left" colspan="1">10&#160;min</td><td rowspan="2" align="left" colspan="1">0.1&#160;M NaOH</td><td align="left" colspan="1" rowspan="1">ex: 430&#160;nm</td></tr><tr><td align="left" colspan="1" rowspan="1">em: 538&#160;nm</td></tr><tr><td rowspan="2" align="left" colspan="1">MRP2</td><td rowspan="2" align="left" colspan="1">CDCF 5&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">benzbromarone 100&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">10&#160;min</td><td rowspan="2" align="left" colspan="1">10&#160;min</td><td rowspan="2" align="left" colspan="1">0.1&#160;M NaOH</td><td align="left" colspan="1" rowspan="1">ex: 510&#160;nm</td></tr><tr><td align="left" colspan="1" rowspan="1">em: 535&#160;nm</td></tr><tr><td rowspan="2" align="left" colspan="1">P-gp</td><td rowspan="2" align="left" colspan="1">NMQ 2&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">verapamil 100&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">15&#160;min</td><td rowspan="2" align="left" colspan="1">3&#160;min</td><td rowspan="2" align="left" colspan="1">3:1 MeOH/H<sub>2</sub>O + 0.1% HCOOH</td><td align="left" colspan="1" rowspan="1">ex: 248&#160;nm</td></tr><tr><td align="left" colspan="1" rowspan="1">em: 442&#160;nm</td></tr><tr><td rowspan="2" align="left" colspan="1">OATP2B1</td><td rowspan="2" align="left" colspan="1">5-CF 2&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">sulfasalazine 50&#160;&#956;M</td><td rowspan="2" align="left" colspan="1">30&#160;min</td><td rowspan="2" align="left" colspan="1">5&#160;min</td><td rowspan="2" align="left" colspan="1">0.1&#160;M NaOH</td><td align="left" colspan="1" rowspan="1">ex: 487&#160;nm</td></tr><tr><td align="left" colspan="1" rowspan="1">em: 517&#160;nm</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>5-CF, 5-carboxyfluorescein; BCRP,
breast cancer resistance protein; CDCF, 5(6)-carboxy-2,7-dichlorofluorescein;
ex, excitation; em, emission; HCOOH, formic acid; LY, Lucifer yellow;
MeOH, methanol; MRP2, multidrug resistance associated protein 2; NaOH,
sodium hydroxide; NMQ, <italic toggle="yes">N</italic>-methyl-quinidine; OATP2B1,
organic anion transporting polypeptide 2B1; and P-gp, P-glycoprotein.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.3"><label>2.3</label><title>HEK293
Uptake Assay</title><p>The inhibition
of OATP2B1 was studied using a HEK293 cell-based uptake assay. HEK293
cells were cultured in DMEM supplemented with 10% FBS at 37 &#176;C
and 5% CO<sub>2</sub> and seeded at 22,500 cells/well on 96-well plates
coated with 0.1 mg/mL poly-<sc>d</sc>-lysine. After 24 h, the medium
was replaced with a transduction mix (DMEM with 10% FBS, 5 mM sodium
butyrate, and recombinant OATP2B1 or enhanced yellow fluorescent protein
[eYFP, negative control] baculoviruses). The baculoviruses were produced
as previously described.<xref rid="ref12" ref-type="bibr"/> The uptake assay
was performed after approximately 48 h. Test and preincubation solutions
were prepared in a transport buffer (25 mM HEPES and 4.17 mM NaHCO<sub>3</sub> in HBSS adjusted to the pH 6 with NaOH) containing the test
compounds (50 &#956;M), DMSO (0.5%), or positive control (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Test solutions
also contained the substrate. Cells were washed with warm transport
buffer and preincubated at 37 &#176;C. Preincubation solutions were
replaced with test solutions and incubated at 37 &#176;C with shaking
at 250 rpm. Transport was terminated by aspirating the test solution
and washing the wells with an ice-cold transport buffer (150 &#956;L)
three times. Wells were left to dry, and cells were lysed with 0.1
M NaOH. Fluorescence was measured with a Varioskan LUX microplate
reader (Thermo Fisher Scientific, Finland). Total protein concentration
was measured from six random wells with a Pierce Coomassie (Bradford)
Assay kit (Thermo Fisher Scientific) to ensure a similar protein concentration
in the OATP2B1 and eYFP wells.</p></sec><sec id="sec2.4"><label>2.4</label><title>Caco-2
Permeability Assay</title><p>Beta-carotene
and six other food additives (allura red AC, brilliant blue FCF, carmoisine,
neohesperidin DC, sunset yellow FCF, and tartrazine) previously identified
as BCRP, MRP2, or OATP2B1 inhibitors<named-content content-type="bibref-group">
<xref rid="ref11" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> were selected for Caco-2 permeability studies to
determine their potential effect on drug permeability through cell
monolayers. Caco-2 cells were cultured on 12-well Transwell polycarbonate
membrane inserts with a 0.4 &#956;m pore size (Corning Incorporated,
Kennebunk, ME) at 37 &#176;C and 5% CO<sub>2</sub> for 21&#8211;24
days prior to the experiment as described in Hubatsch et al.<xref rid="ref42" ref-type="bibr"/> The culture medium (DMEM, 10% FBS, 1% MEM nonessential
amino acids, 100 U/mL penicillin&#8211;streptomycin) was changed
every second day. Transepithelial electrical resistance (TEER) was
measured before and after the permeability assay with a Millicell-ERS
electrode (Millipore, Bedford, MA) attached to an epithelial volt
ohm meter (EVOM, World Precision Instruments, Sarasota, FL). The permeability
assay was performed according to a previously published protocol.<xref rid="ref42" ref-type="bibr"/> In short, the food additives, sulfasalazine
(substrate), Ko-143 (BCRP control inhibitor), and LY (paracellular
marker) were diluted in a transport buffer (25 mM HEPES and 4.17 mM
NaHCO<sub>3</sub> in HBSS adjusted to pH 7.4 with NaOH). Sulfasalazine
is a substrate of BCRP and OATP2B1.<named-content content-type="bibref-group">
<xref rid="ref43" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>
</named-content> The DMSO concentration
was 0.45&#8211;1.5%. Before the experiment, inserts were washed and
preincubated in the transport buffer for 20 min shaking at 37 &#176;C.
Sulfasalazine and LY permeability was measured in the apical to basolateral
direction at five time points (20, 40, 60, 90, and 120 min) and, additionally,
in the basolateral to apical direction to calculate the efflux ratio.
Food additives (50&#8211;200 &#956;M) were added on the apical side
together with sulfasalazine (500 &#956;M). Ko-143 (10 &#956;M) was
used on both the apical and basolateral sides to obtain maximal BRCP
inhibition. LY (250 &#956;M) was added on the donor side of all inserts
to measure the integrity of the cell monolayer. Before analysis, samples
were centrifuged at 2755<italic toggle="yes">g</italic> for 30 min, and donor solution
and mass balance samples were diluted 1:100. LY fluorescence was measured
with a Varioskan LUX microplate reader (Thermo Fisher Scientific)
at 430 nm excitation and 538 nm emission. Sulfasalazine was analyzed
with ultra-performance liquid chromatography (UPLC) using a Syncronis
C18 column (1.7 &#956;m particle size, 50 &#215; 2.1 mm + 0.2 &#956;m Waters
online filter) (Thermo Fisher Scientific) coupled with Waters Acquity
UPLC interfaced with a PDA detector both controlled by the Waters
Empower software version 3. The UPLC was operated in gradient mode
at 354 nm. Solvents were 0.015 M phosphate buffer pH 2 (A), acetonitrile
(B), 1:1 acetonitrile/methanol (strong needle wash), and 20% acetonitrile
(weak needle wash). Column temperature was 30 &#176;C, injection volume
was 10 &#956;L, retention time was 1.46 min, and flow rate was 0.5
mL/min. The gradient was 25% B &#8594; 70% B (0&#8211;3 min), 70%
B &#8594; 25% B (3.00&#8211;3.01 min), and 25% B (3.01&#8211;4
min). The data were collected for the first 180 s of each UPLC run.</p></sec><sec id="sec2.5"><label>2.5</label><title>Data Analysis</title><p>The ATP- or OATP2B1-dependent
transport in the presence of each of the studied food additives was
calculated and then compared with the corresponding transport observed
for the vehicle (DMSO) control to calculate the relative transport.
For the efflux transporters, the relative transport was calculated
as<disp-formula id="ueq1"><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00705_m001.jpg"/><mml:math id="d1e541" display="block"><mml:mi>relative</mml:mi><mml:mspace width="0.25em"/><mml:mi>transport</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>control</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>transport</mml:mi><mml:mrow><mml:mi>inh</mml:mi><mml:mo>,</mml:mo><mml:mi>ATP</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>transport</mml:mi><mml:mrow><mml:mi>inh</mml:mi><mml:mo>,</mml:mo><mml:mi>no</mml:mi><mml:mspace width="0.25em"/><mml:mi>ATP</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>transport</mml:mi><mml:mrow><mml:mi>DMSO</mml:mi><mml:mo>,</mml:mo><mml:mi>ATP</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>transport</mml:mi><mml:mrow><mml:mi>DMSO</mml:mi><mml:mo>,</mml:mo><mml:mi>no</mml:mi><mml:mspace width="0.25em"/><mml:mi>ATP</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></alternatives></disp-formula>where transport<sub>inh,ATP</sub> and transport<sub>inh,no&#160;ATP</sub> are the transport rates in the presence of
food additives with or without ATP, respectively, and transport<sub>DMSO,ATP</sub> and transport<sub>DMSO,no&#160;ATP</sub> are the corresponding
transport rates in the presence of the vehicle (DMSO) with or without
ATP. For OATP2B1, the relative transport was calculated as<disp-formula id="ueq2"><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00705_m002.jpg"/><mml:math id="d1e605" display="block"><mml:mi>relative</mml:mi><mml:mspace width="0.25em"/><mml:mi>transport</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>control</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>uptake</mml:mi><mml:mrow><mml:mi>inh</mml:mi><mml:mo>,</mml:mo><mml:mi>OATP</mml:mi><mml:mn>2</mml:mn><mml:mi mathvariant="normal">B</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>uptake</mml:mi><mml:mrow><mml:mi>inh</mml:mi><mml:mo>,</mml:mo><mml:mi>EYFP</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>uptake</mml:mi><mml:mrow><mml:mi>DMSO</mml:mi><mml:mo>,</mml:mo><mml:mi>OATP</mml:mi><mml:mn>2</mml:mn><mml:mi mathvariant="normal">B</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>uptake</mml:mi><mml:mrow><mml:mi>DMSO</mml:mi><mml:mo>,</mml:mo><mml:mi>EYFP</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></alternatives></disp-formula>where uptake<sub>inh,OATP2B1</sub> and uptake<sub>DMSO,OATP2B1</sub> describe the uptake of the substrate in the presence
of food additives or the vehicle (DMSO), respectively, in OATP2B1
transduced cells and uptake<sub>inh,EYFP</sub> and uptake<sub>DMSO,EYFP</sub> describe the background passive uptake of the substrate in the presence
of food additives or the vehicle (DMSO), respectively, in eYFP-transduced
cells.</p><p>The half-maximal inhibitory concentrations (IC<sub>50</sub>) were calculated with GraphPad Prism version 9.0.2 (GraphPad Software,
San Diego, CA) using nonlinear regression that fits the data to a
four-parameter dose&#8211;response curve:<disp-formula id="ueq3"><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00705_m003.jpg"/><mml:math id="d1e676" display="block"><mml:mi>relative</mml:mi><mml:mspace width="0.25em"/><mml:mi>transport</mml:mi><mml:mo>=</mml:mo><mml:mi>minimum</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>maximum</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>minimum</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mi>IC</mml:mi><mml:mn>50</mml:mn></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mi>h</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula>where minimum
and maximum describe the plateaus
of minimal and maximal relative transport (%), [<italic toggle="yes">I</italic>] is the concentration of inhibitor, and <italic toggle="yes">h</italic> is the
Hill slope, which describes the steepness of the slope.</p><p>In the
Caco-2 permeability assay, the apparent permeability (<italic toggle="yes">P</italic>
<sub>app</sub>) of sulfasalazine was calculated using the
following equation:<disp-formula id="ueq4"><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00705_m004.jpg"/><mml:math id="d1e724" display="block"><mml:msub><mml:mi>P</mml:mi><mml:mi>app</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>A</mml:mi><mml:mo>&#215;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>where d<italic toggle="yes">Q</italic>/d<italic toggle="yes">t</italic> is the rate of permeation across the cells (nmol/min), <italic toggle="yes">A</italic> is the surface area of the filter (1.12 cm<sup>2</sup>), and <italic toggle="yes">C</italic>
<sub>0</sub> is the initial concentration in the donor
chamber (&#956;M). The efflux ratio of sulfasalazine was calculated
by dividing the <italic toggle="yes">P</italic>
<sub>app</sub> in the basolateral
to the apical direction by the <italic toggle="yes">P</italic>
<sub>app</sub> in
the apical to basolateral direction. The TEER for each cell insert
was calculated before and after the experiment by multiplying the
mean resistance of three measurements by the surface area of the filter
(1.12 cm<sup>2</sup>). Mass balance was calculated by dividing the
sulfasalazine amount in the donor chamber at 0 min by the total amount
of sulfasalazine at 120 min in both chambers. All experiments were
done in triplicate wells, and the IC<sub>50</sub> and Caco-2 permeability
assays were repeated three times.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Identification of Transporter Inhibitors</title><p>Food additives
that inhibited substrate accumulation by &#8805;50%
in single-concentration (50 &#956;M) assays were classified as possible
inhibitors. These additives were beta-carotene and three antioxidants
(octyl gallate, dodecyl gallate, and butylated hydroxytoluene). Beta-carotene
inhibited P-gp, BCRP, and OATP2B1 (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>), and octyl gallate inhibited BCRP and OATP2B1.
Dodecyl gallate inhibited only BCRP, and butylated hydroxytoluene
was the only food additive that had inhibition potency toward MRP2.
Other tested food additives did not inhibit the transporters or had
a less than 50% inhibitory effect.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Transporter inhibition by food additives
(50 &#956;M). Inhibition
of BCRP, MRP2, and P-gp transport was studied in a vesicular transport
assay using Lucifer yellow (50 &#956;M), 5(6)-carboxy-2,7-dichlorofluorescein
(5 &#956;M), and <italic toggle="yes">N</italic>-methyl-quinidine (2 &#956;M)
as substrates, respectively. Inhibition of OATP2B1-mediated uptake
was studied in HEK293 cells using 5-carboxyfluorescein (2 &#956;M)
as a substrate. Results are presented as relative transport activity
normalized to the control ATP-dependent transport or OATP2B1-mediated
uptake (DMSO, 100%). The positive control inhibitors used were sulfasalazine
(50 &#956;M) for BCRP and OATP2B1, benzbromarone (100 &#956;M) for
MRP2, and verapamil (100 &#956;M) for P-gp. Bars show the mean &#177;
SD from three replicate wells; <italic toggle="yes">n</italic> = 1.</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="mp5c00705_0001.jpg"/></fig><p>Beta-carotene, butylated hydroxytoluene, and dodecyl
gallate were
selected as novel inhibitors for dose&#8211;response studies to determine
the IC<sub>50</sub> values (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). All IC<sub>50</sub> values were below 50 &#956;M,
in line with the results in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>. The lowest IC<sub>50</sub> value (3.2 &#956;M) was
observed for the beta-carotene inhibition of P-gp (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Dose&#8211;response
curves of transporter inhibition by food additives.
BCRP inhibition by beta-carotene and dodecyl gallate, P-gp inhibition
by beta-carotene, and MRP2 inhibition by butylated hydroxytoluene
were studied in a vesicular transport assay using Lucifer yellow (50
&#956;M), <italic toggle="yes">N</italic>-methyl-quinidine (2 &#956;M), and 5(6)-carboxy-2,7-dichlorofluorescein
(5 &#956;M) as substrates, respectively. OATP2B1 inhibition by beta-carotene
was studied in HEK293 cells using 5-carboxyfluorescein (2 &#956;M)
as a substrate. Circles represent means from three independent experiments
(<italic toggle="yes">n</italic> = 3) performed in triplicate wells, and the curves
show nonlinear regression.</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="mp5c00705_0002.jpg"/></fig><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Half-Maximal Inhibitory Concentrations
(IC<sub>50</sub>) of Beta-Carotene, Butylated Hydroxytoluene, Dodecyl
Gallate, and Octyl Gallate and Previously Characterized Inhibitors
Selected for the Caco-2 Assay</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="4" align="center" rowspan="1">IC<sub>50</sub> (95% CI), &#956;M<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">BCRP</th><th align="center" colspan="1" rowspan="1">P-gp</th><th align="center" colspan="1" rowspan="1">OATP2B1</th><th align="center" colspan="1" rowspan="1">MRP2</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">beta-carotene</td><td align="left" colspan="1" rowspan="1">12.1 (9.9&#8211;15.5)</td><td align="left" colspan="1" rowspan="1">3.2 (2.4&#8211;4.3)</td><td align="left" colspan="1" rowspan="1">27.5 (22.6&#8211;35.6)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">butylated hydroxytoluene</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">49.0 (43.1&#8211;55.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">dodecyl
gallate</td><td align="left" colspan="1" rowspan="1">22.5 (16.4&#8211;31.2)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">octyl gallate</td><td align="left" colspan="1" rowspan="1">10.0 (6.4&#8211;15.7)<xref rid="ref45" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">19.2 (14.8&#8211;24.9)<xref rid="ref45" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">allura
red AC</td><td align="left" colspan="1" rowspan="1">13.3;<xref rid="ref11" ref-type="bibr"/> 4.42<xref rid="ref16" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">0.8<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn1" ref-type="table-fn"/>; 1.6<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn2" ref-type="table-fn"/>; 2.59<xref rid="ref17" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">20.0<xref rid="ref11" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">brilliant blue FCF</td><td align="left" colspan="1" rowspan="1">1.97<xref rid="ref16" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">18.4<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn2" ref-type="table-fn"/>; 13.0<xref rid="ref17" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">3.22<xref rid="ref11" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">carmoisine</td><td align="left" colspan="1" rowspan="1">5.38<xref rid="ref11" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">9.7<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn1" ref-type="table-fn"/>; 2.9<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">29.0<xref rid="ref11" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">neohesperidin DC</td><td align="left" colspan="1" rowspan="1">0.86<xref rid="ref11" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">48.6<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn1" ref-type="table-fn"/>; 15.5<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn2" ref-type="table-fn"/>; 20.1<xref rid="ref17" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">sunset yellow FCF</td><td align="left" colspan="1" rowspan="1">10.6;<xref rid="ref11" ref-type="bibr"/> 14.1<xref rid="ref16" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">20.3<xref rid="ref12" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn2" ref-type="table-fn"/>; 68.4<xref rid="ref17" ref-type="bibr"/>
<sup>,</sup>
<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">tartrazine</td><td align="left" colspan="1" rowspan="1">23.5;<xref rid="ref11" ref-type="bibr"/> 5.61<xref rid="ref16" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>pH 7.4.</p></fn><fn id="t2fn2"><label>b</label><p>pH
5.5.</p></fn><fn id="t2fn3"><label>c</label><p>
<italic toggle="yes">K</italic>
<sub>i</sub>.</p></fn></table-wrap-foot></table-wrap><p>Assay interference
studies were performed to rule
out possible
false inhibition results (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00705/suppl_file/mp5c00705_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>). Beta-carotene interfered with the fluorescence of all four substrates
by more than 20% at the highest possible concentration, and for LY
and 5-CF, quenching up to &#8764;30% was seen also with lower beta-carotene
concentrations (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00705/suppl_file/mp5c00705_si_001.pdf" ext-link-type="uri">Figure S1</ext-link>). Dodecyl gallate
quenched the fluorescence of LY by &#8805;20% at the highest concentration,
but octyl gallate and butylated hydroxytoluene did not interfere with
the fluorescence of any of the compounds.</p></sec><sec id="sec3.2"><label>3.2</label><title>Caco-2
Permeability Assay</title><p>To further
study the inhibitory potential of food additives, the effect of seven
additives on sulfasalazine permeability was studied in Caco-2 Transwell
cultures. The low <italic toggle="yes">P</italic>
<sub>app</sub> of LY (&#8804;0.1
&#215; 10<sup>&#8211;6</sup> cm/s), high TEER values (&gt;300 &#937;
cm<sup>2</sup>), and high sulfasalazine efflux ratio (&gt;70) imply
that
the Caco-2 cells formed a tight polarized monolayer with low paracellular
permeability and efflux transporters expressed at the apical side.
None of the food additives affected the <italic toggle="yes">P</italic>
<sub>app</sub> of sulfasalazine when added only on the apical side (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). Apical to basolateral <italic toggle="yes">P</italic>
<sub>app</sub> for sulfasalazine alone and with any of
the food additives was &#8804;0.1 &#215; 10<sup>&#8211;6</sup> cm/s.
The control inhibitor Ko-143 increased the permeability to &#8764;0.6
&#215; 10<sup>&#8211;6</sup> cm/s. For sulfasalazine alone, the basolateral
to apical <italic toggle="yes">P</italic>
<sub>app</sub> was &#8764;6.5 &#215;
10<sup>&#8211;6</sup> cm/s. The inhibition potential of Ko-143 was
weaker when it was applied only on the apical side (<italic toggle="yes">P</italic>
<sub>app</sub> fold change &#8804; 2) of Caco-2 cells compared to
when it was on the apical and basolateral sides (<italic toggle="yes">P</italic>
<sub>app</sub> fold change &#8805; 5). Thus, we tested the effects
of two of the food additives, tartrazine and carmoisine, when added
on both sides of the cell monolayer, but the effect on sulfasalazine
permeability was negligible (<italic toggle="yes">P</italic>
<sub>app</sub> fold
change &#8804; 2) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00705/suppl_file/mp5c00705_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>). After the
experiment, the mass balance of sulfasalazine was &gt;90% in all wells.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Effects of selected food additives on the sulfasalazine
permeability
in Caco-2 cells. The inhibition of transporters by seven food additives
was studied in Caco-2 cells by measuring the apparent permeability
(<italic toggle="yes">P</italic>
<sub>app</sub>) of sulfasalazine. Food additives
(200 &#956;M, except for neohesperidin (100 &#956;M)) were added
to the apical side of the Caco-2 cell monolayer, and sulfasalazine
(500 &#956;M) permeability was measured in the apical to basolateral
direction. Ko-143 (10 &#956;M) was used as the control inhibitor.
DMSO concentration was 0.45% unless otherwise stated. Circles present <italic toggle="yes">P</italic>
<sub>app</sub> from three replicate wells from a representative
study, and lines show the mean. A&#8211;B = apical to basolateral;
B&#8211;A = basolateral to apical.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="mp5c00705_0003.jpg"/></fig></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p>The potential of food additives
to cause drug interactions is unclear.
Many food additives have been identified in vitro as inhibitors of
intestinal drug transporters.<named-content content-type="bibref-group">
<xref rid="ref11" ref-type="bibr"/>&#8722;<xref rid="ref12" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref13" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref14" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref17" ref-type="bibr"/>
</named-content> However, their effect on transcellular permeability has rarely been
studied. Here, we tested the inhibitory potential of 22 food additives
on BCRP, P-gp, MRP2, and OATP2B1 mediated transport and further evaluated
the effects of seven food additives on sulfasalazine permeability
over a Caco-2 monolayer.</p><p>In the initial testing, we found four
potential inhibitors: beta-carotene,
butylated hydroxytoluene, dodecyl gallate, and octyl gallate. Dose&#8211;response
studies confirmed that these compounds cause 50% inhibition at &#8804;50
&#956;M. Despite beta-carotene partially quenching the fluorescence
signal (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00705/suppl_file/mp5c00705_si_001.pdf" ext-link-type="uri">Figure S1</ext-link>), its concentration is
presumed to be low during fluorescent measurement, and thus, we conclude
that it is an inhibitor of BCRP, P-gp, and OATP2B1. In addition, the
inhibitory activity is probably not due to membrane effects as beta-carotene
did not inhibit MRP2. Previous studies support this finding of inhibition,
as beta-carotene was identified as an inhibitor of P-gp in Caco-2
cells,<xref rid="ref46" ref-type="bibr"/> and it significantly inhibited
the transport of calcein-AM, rhodamine 123, and doxorubicin in <italic toggle="yes">ABCB1</italic>/Flp-In-293 cells,<xref rid="ref47" ref-type="bibr"/> while
it had only weak inhibition potency toward BCRP.<xref rid="ref47" ref-type="bibr"/> Also in our study, P-gp inhibition was stronger than BCRP
inhibition, but the difference was small. Interestingly, beta-apo-8&#8217;-carotenal
did not inhibit these transporters as markedly as beta-carotene, although
their structures are similar.</p><p>There is contradictory information
about the inhibition potency
of octyl gallate. In our previous study, octyl gallate inhibited BCRP
and MRP2<xref rid="ref45" ref-type="bibr"/> (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). Here, octyl gallate did not inhibit MRP2
or P-gp, and for OATP2B1, only 65% inhibition was seen at 50 &#956;M.
Due to the relatively weak inhibition, we did not include OATP2B1
in octyl gallate dose&#8211;response studies. Contrary to our results,
octyl gallate and dodecyl gallate inhibited the function of P-gp in
KB-C2 cells.<xref rid="ref48" ref-type="bibr"/>
</p><p>When Kulkarni et al.<xref rid="ref15" ref-type="bibr"/> studied the effect
of antioxidants on BCRP, OATP2B1, and P-gp, butylated hydroxytoluene
did not inhibit any of the transporters, which is in line with our
results. Moreover, it was observed that butylated hydroxytoluene had
an OATP2B1-stimulating effect in both their and our studies. Kulkarni
et al.<xref rid="ref15" ref-type="bibr"/> identified butylated hydroxyanisole
as a significant inhibitor of all three transporters, but the determined
IC<sub>50</sub> values were higher than 50 &#956;M, especially for
BCRP and P-gp. Similarly, in our study, butylated hydroxyanisole did
not inhibit BCRP, OATP2B1, or P-gp more than 50% at 50 &#956;M. Bajaj
et al.<xref rid="ref14" ref-type="bibr"/> studied the interaction of 123
commonly used oral molecular excipients with P-gp. None of the excipients,
which were included in both our and their studies (&#945;-tocopherol,
ascorbic acid, butylated hydroxytoluene, erythritol, isomalt, lactitol,
maltitol, mannitol, propyl gallate, sorbitol, and xylitol), inhibited
P-gp.</p><p>Intestinal drug concentrations that rise above 10-fold
their IC<sub>50</sub> values are considered relevant for clinical
drug interactions.<xref rid="ref24" ref-type="bibr"/> To use the same cutoff
value for food additives,
their concentrations in food and beverages and amount of intake should
be known. The daily dietary intake for beta-carotene, whose richest
sources are yellow, orange, and green leafy fruits and vegetables,
is estimated to be 1.46&#8211;5.84 mg.<named-content content-type="bibref-group">
<xref rid="ref49" ref-type="bibr"/>&#8722;<xref rid="ref50" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref51" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref52" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref53" ref-type="bibr"/>
</named-content> However, the daily intake of beta-carotene may increase
considerably if a dietary supplement is used. These supplements can
contain up to 100 mg of beta-carotene, which might increase its intestinal
concentration to 745 &#956;M, which is over 27-fold the IC<sub>50</sub> values determined here. The concentrations of allura red, carmoisine,
sunset yellow, and tartrazine in beverages can be as high as &#8764;850&#8211;2300
mg/L,<named-content content-type="bibref-group">
<xref rid="ref54" ref-type="bibr"/>,<xref rid="ref55" ref-type="bibr"/>
</named-content> and thus, their intestinal concentrations
also may temporarily be high and exceed the IC<sub>50</sub> values
by 33&#8211;5880-fold, which would warrant further studies based
on the current ICH drug interaction guidance. In the EU, up to 200
mg/L of colorants are accepted in certain beverages.<xref rid="ref7" ref-type="bibr"/>
</p><p>In the Caco-2 assay, food additives were tested at
50&#8211;200
&#956;M to mimic high-level consumption in the EU. Butylated hydroxytoluene,
dodecyl gallate, and octyl gallate were not included in these studies
since based on the determined IC<sub>50</sub> values, the level of
inhibition at their maximal expected intestinal concentrations is
expected to be low. In addition, dodecyl gallate and octyl gallate
were removed from the EU list of approved food additives in 2018 due
to the lack of sufficient toxicological data.<xref rid="ref56" ref-type="bibr"/>
</p><p>Caco-2 cells have been used to study drug permeability across
cell
monolayers to mimic intestinal absorption for over 20 years,<xref rid="ref57" ref-type="bibr"/> and regulatory agencies recommend their use
in transporter DDI studies.<xref rid="ref24" ref-type="bibr"/> When grown
on semipermeable membranes, Caco-2 cells form polarized cell monolayers
with tight junctions and microvilli.<xref rid="ref58" ref-type="bibr"/> They
express most of the clinically relevant membrane transporters that
are present in the intestine, but their expression levels (e.g., OATP2B1)
may be higher in Caco-2 cells.<named-content content-type="bibref-group">
<xref rid="ref59" ref-type="bibr"/>&#8722;<xref rid="ref60" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref61" ref-type="bibr"/>
</named-content> BCRP, P-gp, and MRP2 are expressed
on the apical membranes of Caco-2 cells,<named-content content-type="bibref-group">
<xref rid="ref62" ref-type="bibr"/>&#8722;<xref rid="ref63" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref64" ref-type="bibr"/>
</named-content> but OATP2B1
may be expressed on both membranes as in the intestine.<named-content content-type="bibref-group">
<xref rid="ref23" ref-type="bibr"/>,<xref rid="ref65" ref-type="bibr"/>,<xref rid="ref66" ref-type="bibr"/>
</named-content>
</p><p>Sulfasalazine is a high-affinity
substrate of BCRP and OATP2B1.<named-content content-type="bibref-group">
<xref rid="ref43" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>
</named-content> We selected it as a
substrate for the Caco-2 assay due to its low
apical to basolateral permeability in vitro and low intestinal absorption
in humans, both of which increase upon BCRP inhibition or dysfunction.<named-content content-type="bibref-group">
<xref rid="ref67" ref-type="bibr"/>,<xref rid="ref68" ref-type="bibr"/>
</named-content> The ICH drug interaction guideline lists sulfasalazine as an in
vitro and clinical substrate of BCRP, encouraging its use in drug
interaction studies.<xref rid="ref24" ref-type="bibr"/> Here, sulfasalazine
permeability was measured in the apical to basolateral direction to
mimic intestinal absorption. At 10 &#956;M, Ko-143 might inhibit
MRP2, OATP2B1, and P-gp even though the inhibitory effect should be
strongest for BCRP (IC<sub>50</sub> &lt; 0.5 &#956;M).<named-content content-type="bibref-group">
<xref rid="ref44" ref-type="bibr"/>,<xref rid="ref69" ref-type="bibr"/>&#8722;<xref rid="ref70" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref71" ref-type="bibr"/>
</named-content> In addition, most of the compounds studied inhibit
both BCRP and OATP2B1 in the overexpression systems (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). This considerable overlap
between transporter substrates and inhibitors might complicate the
interpretation of Caco-2 assay results. For example, the inhibition
of apical BCRP should increase the apical to basolateral permeability
of sulfasalazine, while the inhibition of apical OATP2B1 could decrease
it. Inhibition of both BCRP and OATP2B1 may show as unchanged permeability,
which could occur in our assay for several additives. However, sulfasalazine
permeability was unchanged even in the presence of tartrazine, which
only inhibits BCRP. Moreover, considering the high efflux ratio of
&gt;70 observed for sulfasalazine (and assuming a primarily apical
expression
of OATP2B1), BCRP is expected to be the main transporter of sulfasalazine
in our Caco-2 cells. The influence of BCRP is also supported by the
sensitivity to Ko-143, which is a stronger inhibitor for BCRP than
for OATP2B1. Therefore, we assume that changes in sulfasalazine permeability
would be primarily mediated by BCRP inhibition. Interestingly, the
inhibition potential of Ko-143 was stronger when it was applied on
the basolateral side compared to the apical side (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00705/suppl_file/mp5c00705_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>), suggesting a more permeable basolateral side.
Despite the complex interpretation of sulfasalazine permeability in
the Caco-2 assay, membrane transporters expressed in Caco-2 cells
are expressed also in the intestine,<xref rid="ref59" ref-type="bibr"/> which
support the relevance of Caco-2 data.</p><p>Differences between the
vesicular transport (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) and Caco-2 assay results (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>) could be explained by the
low permeability of the food additives. The vesicular transport assay
may overestimate the inhibitory potential of water-soluble compounds,
such as synthetic food dyes, since the intracellular side of the transporter
is facing outward and can directly interact with extravesicular compounds.
In Caco-2 cells, if the transporter interaction site is intracellular,
e.g., the ATP-binding site or the substrate binding cavity, compounds
have to permeate through the cell membrane before binding to the transporter.
Allura red AC, brilliant blue FCF, carmoisine, sunset yellow FCF,
and tartrazine are water-soluble (LogD<sub>7.4</sub> &lt; 0), and
according to EFSA&#8217;s evaluations, their in vivo absorption is
expected to be low.<named-content content-type="bibref-group">
<xref rid="ref72" ref-type="bibr"/>&#8722;<xref rid="ref73" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref74" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref75" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref76" ref-type="bibr"/>
</named-content> Thus, they are likely unable to permeate through cell membranes
to inhibit efflux transporters. Inhibition of uptake transporters
is, however, possible as Zou et al.<xref rid="ref17" ref-type="bibr"/> found
that 25 mg/kg allura red AC inhibits OATP2B1 and decreases fexofenadine
plasma levels in P-gp-deficient mice.</p><p>Beta-carotene and neohesperidin
DC are more lipophilic (LogD<sub>7.4</sub> = 13.6 and 2.6, respectively)
than the five colorants and
could thus more readily partition into the cell membrane. This has
been seen in Caco-2 cells where the absorption efficiency of beta-carotene
from a micellar formulation into cells was up to &#8764;11%, and
up to &#8764;35% of the applied beta-carotene dose was recovered
in the basolateral chamber.<named-content content-type="bibref-group">
<xref rid="ref77" ref-type="bibr"/>,<xref rid="ref78" ref-type="bibr"/>
</named-content> Also, neohesperidin
DC had moderate permeability (<italic toggle="yes">P</italic>
<sub>app</sub> &lt;
6 &#215; 10<sup>&#8211;6</sup> cm/s) in Caco-2 cells,<xref rid="ref79" ref-type="bibr"/> and in rats, its oral bioavailability was &#8764;20%.<xref rid="ref80" ref-type="bibr"/> Despite the better permeability, the lipophilicity
of neohesperidin DC and beta-carotene can cause solubility problems
in aqueous assay buffers. Their aggregation may cause nonspecific
inhibition<xref rid="ref81" ref-type="bibr"/> or prevent uptake into cells.
In our assay, the DMSO stocks of food additives were diluted in the
buffer and applied to Caco-2 cells. Micellization could have improved
the solubility and uptake of beta-carotene.</p><p>Another possible
explanation for the unchanged sulfasalazine permeability
is the lack of preincubation with food additives. It is known that
adding a preincubation step to inhibition studies of SLC transporters
can increase the inhibitory potential compared to the coincubation
method,<named-content content-type="bibref-group">
<xref rid="ref82" ref-type="bibr"/>,<xref rid="ref83" ref-type="bibr"/>
</named-content> and hence, we used preincubation in the
OATP2B1 inhibition studies in HEK293 cells. The proposed mechanism
for the preincubation effect is that the inhibitor has enough time
to reach the intracellular interaction side of transporters.<named-content content-type="bibref-group">
<xref rid="ref82" ref-type="bibr"/>,<xref rid="ref84" ref-type="bibr"/>
</named-content> In the Caco-2 assay, the coincubation time with the inhibitor and
substrate is considerably longer (i.e., 120 min) than in SLC uptake
assays, e.g., in HEK293 cells (2&#8211;10 min). This long coincubation
time may facilitate the permeation of the inhibitor and thus reduce
the impact of preincubation.<named-content content-type="bibref-group">
<xref rid="ref82" ref-type="bibr"/>,<xref rid="ref85" ref-type="bibr"/>
</named-content> However, it would be
interesting to study the preincubation effect also in Caco-2 cells
since food additives are not always consumed together with drugs.</p><p>In addition to the dose and time of administration, other factors
affect the inhibitory potential of food additives in humans. For example,
human intestinal microflora can metabolize food additives such as
sweeteners and azo dyes,<named-content content-type="bibref-group">
<xref rid="ref86" ref-type="bibr"/>&#8722;<xref rid="ref87" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref88" ref-type="bibr"/>
</named-content> which could diminish their inhibitory
effects. Zou et al.<xref rid="ref17" ref-type="bibr"/> hypothesize, however,
that high concentrations of azo dyes in the intestine might be able
to saturate azoreductase capacity of gut microbiome, which also highlights
the importance of predicting the intestinal concentrations of food
additives. Nevertheless, it should be noted that the concentration
inside the enterocyte can differ from the intestinal concentration.
The intracellular concentration is especially important when considering
the function of efflux transporters since their interaction site is
usually intracellular.<named-content content-type="bibref-group">
<xref rid="ref89" ref-type="bibr"/>,<xref rid="ref90" ref-type="bibr"/>
</named-content> Hence, more in vivo and clinical
studies are needed to fully understand the effects of food additives.
A final limitation of our inhibition studies may be that transporter
inhibition can be substrate-dependent. For example, it is known that
P-gp has multiple binding sites,<named-content content-type="bibref-group">
<xref rid="ref91" ref-type="bibr"/>,<xref rid="ref92" ref-type="bibr"/>
</named-content> and thus,
inhibition of substrate transport does not fully reflect the inhibitory
ability of the food additive if its interaction site is different
from that of the used substrate. Since only one substrate was used
in the initial assays (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), our results do not definitively rule out the possibility
of inhibition.</p></sec><sec id="sec5"><label>5</label><title>Conclusions</title><p>From
the 22 tested food
additives, four (beta-carotene, butylated
hydroxytoluene, dodecyl gallate, and octyl gallate) inhibit intestinal
drug transporters in vitro in overexpression systems. However, when
seven food additives with inhibitory effects toward intestinal drug
transporters were tested in Caco-2 cells, their effect on sulfasalazine
permeability was negligible. These results suggest that even though
many food additives can inhibit drug transporters, they might have
limited effect on drug permeability and absorption from the intestine.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="mp5c00705_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>We would like to acknowledge Timo Oksanen
for the
sulfasalazine UPLC analysis and the Drug Discovery and Chemical Biology
Network, funded by Biocenter Finland, for providing access to screening
instrumentation.</p></ack><notes id="notes2" notes-type="si"><p>The
Supporting Information is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00705?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00705</ext-link>.<list list-type="simple" id="silist"><list-item><p>Results from fluorescent
interaction studies and effect
of Ko-143 on sulfasalazine permeability from the apical, basolateral,
or apical and basolateral side of Caco-2 cells (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00705/suppl_file/mp5c00705_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes1" notes-type="author-contributions"><label>1</label><p>L.S. and E.S. contributed equally to this work.</p></notes><notes id="notes4" notes-type="funding-statement"><p>This work was
supported, in part, by the Academy of Finland (No. 332949), the Doctoral
Education Pilot in Precision Cancer Medicine (iCANDOC), GeneCellNano
Flagship, and the Swedish Cultural Foundation in Finland.</p></notes><notes id="notes3" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Baker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>P.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sievert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Backholer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hadjikakou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huse</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scrinis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Worsley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Friel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>M.</given-names></name><article-title>Ultra-Processed
Foods and the Nutrition Transition: Global, Regional and National
Trends, Food Systems Transformations and Political Economy Drivers</article-title><source>Obes. Rev.</source><year>2020</year><volume>21</volume><issue>12</issue><elocation-id>e13126</elocation-id><pub-id pub-id-type="doi">10.1111/obr.13126</pub-id><pub-id pub-id-type="pmid">32761763</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Chazelas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Deschasaux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Srour</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kesse-Guyot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Julia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alles</surname><given-names>B.</given-names></name><name name-style="western"><surname>Druesne-Pecollo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hercberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Latino-Martel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Esseddik</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Slamich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gigandet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Touvier</surname><given-names>M.</given-names></name><article-title>Food Additives: Distribution and Co-Occurrence in 126,000
Food Products of the French Market</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>3980</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-60948-w</pub-id><pub-id pub-id-type="pmid">32132606</pub-id><pub-id pub-id-type="pmcid">PMC7055242</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Dunford</surname><given-names>E. K.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Popkin</surname><given-names>B.</given-names></name><article-title>Food Additives
in Ultra-Processed
Packaged Foods: An Examination of US Household Grocery Store Purchases</article-title><source>J. Acad. Nutr. Diet.</source><year>2023</year><volume>123</volume><issue>6</issue><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.jand.2022.11.007</pub-id><pub-id pub-id-type="pmid">36931919</pub-id><pub-id pub-id-type="pmcid">PMC10200736</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Monteiro</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Moubarac</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Louzada</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Rauber</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khandpur</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cediel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Neri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martinez-Steele</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baraldi</surname><given-names>L. G.</given-names></name><name name-style="western"><surname>Jaime</surname><given-names>P. C.</given-names></name><article-title>Ultra-Processed
Foods: What They Are and How to Identify Them</article-title><source>Public Health Nutr.</source><year>2019</year><volume>22</volume><issue>5</issue><fpage>936</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1017/S1368980018003762</pub-id><pub-id pub-id-type="pmid">30744710</pub-id><pub-id pub-id-type="pmcid">PMC10260459</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Moubarac</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Batal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Louzada</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Martinez
Steele</surname><given-names>E.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>C. A.</given-names></name><article-title>Consumption of Ultra-Processed Foods
Predicts Diet
Quality in Canada</article-title><source>Appetite</source><year>2017</year><volume>108</volume><fpage>512</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.appet.2016.11.006</pub-id><pub-id pub-id-type="pmid">27825941</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Slimani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Deharveng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Southgate</surname><given-names>D. A. T.</given-names></name><name name-style="western"><surname>Biessy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chaj&#232;s</surname><given-names>V.</given-names></name><name name-style="western"><surname>van Bakel</surname><given-names>M. M. E.</given-names></name><name name-style="western"><surname>Boutron-Ruault</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>McTaggart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grioni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verkaik-Kloosterman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huybrechts</surname><given-names>I.</given-names></name><name name-style="western"><surname>Amiano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jenab</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vignat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bouckaert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Casagrande</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zourna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Trichopoulou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wirf&#228;lt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rohrmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Illner</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Barricarte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Touvier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niravong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ock&#233;</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>van der Schouw</surname><given-names>Y. T.</given-names></name><name name-style="western"><surname>Bendinelli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lauria</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brustad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hjart&#229;ker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tj&#248;nneland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Riboli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bingham</surname><given-names>S.</given-names></name><article-title>Contribution of Highly Industrially Processed Foods
to the Nutrient Intakes and Patterns of Middle-Aged Populations in
the European Prospective Investigation into Cancer and Nutrition Study</article-title><source>Eur. J. Clin. Nutr.</source><year>2009</year><volume>63</volume><issue>S4</issue><fpage>S206</fpage><lpage>S225</lpage><pub-id pub-id-type="doi">10.1038/ejcn.2009.82</pub-id><pub-id pub-id-type="pmid">19888275</pub-id></element-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><source>Food and feed information portal database version 5.3. European Comission
Food and Feed Information Portal Database. Based on Annex II of Regulation
(EC) No 1333/2008</source>. <uri xlink:href="https://ec.europa.eu/food/food-feed-portal/screen/food-additives/search">https://ec.europa.eu/food/food-feed-portal/screen/food-additives/search</uri> (accessed 2025&#8211;02&#8211;20).</mixed-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Engel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oswald</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>W.</given-names></name><name name-style="western"><surname>Keiser</surname><given-names>M.</given-names></name><article-title>Pharmaceutical Excipients
Influence the Function of Human Uptake Transporting Proteins</article-title><source>Mol. Pharmaceutics</source><year>2012</year><volume>9</volume><issue>9</issue><fpage>2577</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1021/mp3001815</pub-id><pub-id pub-id-type="pmid">22808947</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Hanke</surname><given-names>U.</given-names></name><name name-style="western"><surname>May</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rozehnal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nagel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weitschies</surname><given-names>W.</given-names></name><article-title>Commonly Used
Nonionic Surfactants Interact Differently with the Human Efflux Transporters
ABCB1 (p-Glycoprotein) and ABCC2 (MRP2)</article-title><source>Eur.
J. Pharm. Biopharm.</source><year>2010</year><volume>76</volume><issue>2</issue><fpage>260</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2010.06.008</pub-id><pub-id pub-id-type="pmid">20600890</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Yamagata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kusuhara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takayama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Benameur</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y.</given-names></name><article-title>Characterization of the Inhibition
of Breast Cancer
Resistance Protein-Mediated Efflux of Mitoxantrone by Pharmaceutical
Excipients</article-title><source>Int. J. Pharm.</source><year>2009</year><volume>370</volume><issue>1</issue><fpage>216</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2008.12.005</pub-id><pub-id pub-id-type="pmid">19118611</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Sj&#246;stedt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rauvala</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tepponen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kidron</surname><given-names>H.</given-names></name><article-title>Interaction
of Food Additives with Intestinal Efflux Transporters</article-title><source>Mol. Pharmaceutics</source><year>2017</year><volume>14</volume><issue>11</issue><fpage>3824</fpage><lpage>3833</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00563</pub-id><pub-id pub-id-type="pmid">28921988</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Tikkanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pierrot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>V. B.</given-names></name><name name-style="western"><surname>Hagstr&#246;m</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koenderink</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Kidron</surname><given-names>H.</given-names></name><article-title>Food Additives as Inhibitors
of Intestinal Drug Transporter OATP2B1</article-title><source>Mol.
Pharmaceutics</source><year>2020</year><volume>17</volume><issue>10</issue><fpage>3748</fpage><lpage>3758</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00507</pub-id><pub-id pub-id-type="pmid">32845645</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Al-Ali</surname><given-names>A. A. A.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Steffansen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>C. U.</given-names></name><article-title>Nonionic
Surfactants Modulate the Transport Activity of ATP-Binding Cassette
(ABC) Transporters and Solute Carriers (SLC): Relevance to Oral Drug
Absorption</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>566</volume><fpage>410</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.05.033</pub-id><pub-id pub-id-type="pmid">31125713</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Bajaj</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tsakalozou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Giacomini</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Kroetz</surname><given-names>D. L.</given-names></name><article-title>Interaction of Commonly Used Oral
Molecular Excipients with P-Glycoprotein</article-title><source>AAPS
J.</source><year>2021</year><volume>23</volume><issue>5</issue><fpage>106</fpage><pub-id pub-id-type="doi">10.1208/s12248-021-00631-8</pub-id><pub-id pub-id-type="pmid">34528148</pub-id><pub-id pub-id-type="pmcid">PMC9148196</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Kulkarni</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koleske</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Lara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rege</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L. X.</given-names></name><name name-style="western"><surname>Lionberger</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Giacomini</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Kroetz</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>S. W.</given-names></name><article-title>Effect
of Antioxidants in Medicinal
Products on Intestinal Drug Transporters</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><issue>5</issue><fpage>647</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics16050647</pub-id><pub-id pub-id-type="pmid">38794309</pub-id><pub-id pub-id-type="pmcid">PMC11124870</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Zou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pottel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khuri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>H. X.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tsakalozou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shoichet</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Giacomini</surname><given-names>K. M.</given-names></name><article-title>Interactions
of Oral Molecular Excipients with Breast
Cancer Resistance Protein</article-title><source>BCRP. Mol. Pharm.</source><year>2020</year><volume>17</volume><issue>3</issue><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00658</pub-id><pub-id pub-id-type="pmid">31990564</pub-id><pub-id pub-id-type="pmcid">PMC8177814</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Zou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spanogiannopoulos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>H.-C.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Khuri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pottel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tsakalozou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shoichet</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Giacomini</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Turnbaugh</surname><given-names>P. J.</given-names></name><article-title>Bacterial Metabolism Rescues the Inhibition of Intestinal
Drug Absorption by Food and Drug Additives</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2020</year><volume>117</volume><issue>27</issue><fpage>16009</fpage><lpage>16018</lpage><pub-id pub-id-type="doi">10.1073/pnas.1920483117</pub-id><pub-id pub-id-type="pmid">32571913</pub-id><pub-id pub-id-type="pmcid">PMC7355017</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Iversen</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>N. E.</given-names></name><name name-style="western"><surname>Dalg&#229;rd
Dunvald</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Potteg&#229;rd</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stage</surname><given-names>T. B.</given-names></name><article-title>Drug Metabolism
and Drug Transport of the 100 Most
Prescribed Oral Drugs</article-title><source>Basic Clin. Pharmacol.
Toxicol.</source><year>2022</year><volume>131</volume><issue>5</issue><fpage>311</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1111/bcpt.13780</pub-id><pub-id pub-id-type="pmid">35972991</pub-id><pub-id pub-id-type="pmcid">PMC9804310</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Fromm</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Kauffmann</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Burk</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Warzok</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schrenk</surname><given-names>D.</given-names></name><article-title>The Effect
of Rifampin Treatment on Intestinal Expression of Human MRP Transporters</article-title><source>Am. J. Pathol.</source><year>2000</year><volume>157</volume><issue>5</issue><fpage>1575</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64794-3</pub-id><pub-id pub-id-type="pmid">11073816</pub-id><pub-id pub-id-type="pmcid">PMC1885746</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Maliepaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Faneyte</surname><given-names>I. F.</given-names></name><name name-style="western"><surname>van Gastelen</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Pijnenborg</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>van De
Vijver</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Scheper</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>J. H.</given-names></name><article-title>Subcellular
Localization and Distribution
of the Breast Cancer Resistance Protein Transporter in Normal Human
Tissues</article-title><source>Cancer Res.</source><year>2001</year><volume>61</volume><issue>8</issue><fpage>3458</fpage><lpage>3464</lpage><pub-id pub-id-type="pmid">11309308</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Thiebaut</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tsuruo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gottesman</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Pastan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Willingham</surname><given-names>M. C.</given-names></name><article-title>Cellular
Localization of the Multidrug-Resistance
Gene Product P-Glycoprotein in Normal Human Tissues</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>1987</year><volume>84</volume><issue>21</issue><fpage>7735</fpage><lpage>7738</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.21.7735</pub-id><pub-id pub-id-type="pmid">2444983</pub-id><pub-id pub-id-type="pmcid">PMC299375</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Keiser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaltheuner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wildberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grube</surname><given-names>M.</given-names></name><name name-style="western"><surname>Partecke</surname><given-names>L. I.</given-names></name><name name-style="western"><surname>Heidecke</surname><given-names>C.-D.</given-names></name><name name-style="western"><surname>Oswald</surname><given-names>S.</given-names></name><article-title>The Organic
Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane
of the Human Jejunum and Caco-2 Monolayers</article-title><source>J. Pharm. Sci.</source><year>2017</year><volume>106</volume><issue>9</issue><fpage>2657</fpage><lpage>2663</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.04.001</pub-id><pub-id pub-id-type="pmid">28408210</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Kobayashi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nozawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Imai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nezu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tamai</surname><given-names>I.</given-names></name><article-title>Involvement of Human
Organic Anion Transporting Polypeptide OATP-B
(SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2003</year><volume>306</volume><issue>2</issue><fpage>703</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.051300</pub-id><pub-id pub-id-type="pmid">12724351</pub-id></element-citation></ref><ref id="ref24"><mixed-citation publication-type="book" id="cit24"><person-group person-group-type="allauthors"><collab>ICH</collab></person-group>. <source>ICH Harmonised Guideline Drug Interaction
Studies M12 -
International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use</source>. <publisher-name>ICH</publisher-name><year>2024</year>.</mixed-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Bailey</surname><given-names>D.
G.</given-names></name><name name-style="western"><surname>Malcolm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>O.</given-names></name><name name-style="western"><surname>David Spence</surname><given-names>J.</given-names></name><article-title>Grapefruit
Juice-Drug Interactions</article-title><source>Br. J. Clin. Pharmacol.</source><year>1998</year><volume>46</volume><issue>2</issue><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.1998.00764.x</pub-id><pub-id pub-id-type="pmid">9723817</pub-id><pub-id pub-id-type="pmcid">PMC1873672</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Drozdzik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Busch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lapczuk</surname><given-names>J.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ostrowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurzawski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oswald</surname><given-names>S.</given-names></name><article-title>Protein Abundance of
Clinically Relevant Drug-Metabolizing Enzymes in the Human Liver and
Intestine: A Comparative Analysis in Paired Tissue Specimens</article-title><source>Clin. Pharmacol. Ther.</source><year>2018</year><volume>104</volume><issue>3</issue><fpage>515</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1002/cpt.967</pub-id><pub-id pub-id-type="pmid">29205295</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Paine</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Ludington</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Haining</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Rettie</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Zeldin</surname><given-names>D. C.</given-names></name><article-title>The Human Intestinal
Cytochrome P450 &#8220;Pie&#8221;</article-title><source>Drug Metab.
Dispos. Biol. Fate Chem.</source><year>2006</year><volume>34</volume><issue>5</issue><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1124/dmd.105.008672</pub-id><pub-id pub-id-type="pmid">16467132</pub-id><pub-id pub-id-type="pmcid">PMC2222892</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Ducharme</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Warbasse</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D. J.</given-names></name><article-title>Disposition
of Intravenous and Oral
Cyclosporine after Administration with Grapefruit Juice</article-title><source>Clin. Pharmacol. Ther.</source><year>1995</year><volume>57</volume><issue>5</issue><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/0009-9236(95)90032-2</pub-id><pub-id pub-id-type="pmid">7768070</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Fuhr</surname><given-names>U.</given-names></name><name name-style="western"><surname>M&#252;ller-Peltzer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lopez-Rojas</surname><given-names>P.</given-names></name><name name-style="western"><surname>J&#252;nemann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Staib</surname><given-names>H. A.</given-names></name><article-title>Effects of Grapefruit
Juice and Smoking on Verapamil Concentrations in Steady State</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2002</year><volume>58</volume><issue>1</issue><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/s00228-002-0436-7</pub-id><pub-id pub-id-type="pmid">11956673</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Kupferschmidt</surname><given-names>H. H. T.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Kr&#228;henb&#252;hl</surname><given-names>S.</given-names></name><article-title>Interaction
between Grapefruit Juice and Midazolam in Humans</article-title><source>Clin. Pharmacol. Ther.</source><year>1995</year><volume>58</volume><issue>1</issue><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0009-9236(95)90068-3</pub-id><pub-id pub-id-type="pmid">7628179</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Lown</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Janardan</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Adair</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Fortlage</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>P. B.</given-names></name><article-title>Grapefruit
Juice Increases Felodipine Oral Availability in Humans by Decreasing
Intestinal CYP3A Protein Expression</article-title><source>J. Clin.
Invest.</source><year>1997</year><volume>99</volume><issue>10</issue><fpage>2545</fpage><lpage>2553</lpage><pub-id pub-id-type="doi">10.1172/JCI119439</pub-id><pub-id pub-id-type="pmid">9153299</pub-id><pub-id pub-id-type="pmcid">PMC508096</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Veronese</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Gillen</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Dorval</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Hauck</surname><given-names>W. W.</given-names></name><name name-style="western"><surname>Pequignot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>H. E.</given-names></name><article-title>Exposure-Dependent
Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit
Juice</article-title><source>J. Clin. Pharmacol.</source><year>2003</year><volume>43</volume><issue>8</issue><fpage>831</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1177/0091270003256059</pub-id><pub-id pub-id-type="pmid">12953340</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Weber</surname><given-names>A.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>R.</given-names></name><name name-style="western"><surname>B&#246;rner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vollanth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Matthey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Balogh</surname><given-names>A.</given-names></name><article-title>Can Grapefruit Juice Influence Ethinylestradiol
Bioavailability?</article-title><source>Contraception</source><year>1996</year><volume>53</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/0010-7824(95)00252-9</pub-id><pub-id pub-id-type="pmid">8631189</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Abdelkawy</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Abdelaziz</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Abdelmageed</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Donia</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>El-Khodary</surname><given-names>N. M.</given-names></name><article-title>Effects
of Green Tea Extract on Atorvastatin Pharmacokinetics in Healthy Volunteers</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>2020</year><volume>45</volume><issue>3</issue><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1007/s13318-020-00608-6</pub-id><pub-id pub-id-type="pmid">31997084</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Akamine</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Komori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kusuhara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamai</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Uno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yasui-Furukori</surname><given-names>N.</given-names></name><article-title>Effects of
One-Time Apple Juice Ingestion on the Pharmacokinetics of Fexofenadine
Enantiomers</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2014</year><volume>70</volume><issue>9</issue><fpage>1087</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1007/s00228-014-1705-y</pub-id><pub-id pub-id-type="pmid">24903351</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Jeon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kotegawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>K. S.</given-names></name><article-title>Apple Juice Greatly Reduces Systemic Exposure to Atenolol</article-title><source>Br. J. Clin. Pharmacol.</source><year>2013</year><volume>75</volume><issue>1</issue><fpage>172</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04324.x</pub-id><pub-id pub-id-type="pmid">22574741</pub-id><pub-id pub-id-type="pmcid">PMC3555056</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Knop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Misaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoier</surname><given-names>E.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Glaeser</surname><given-names>H.</given-names></name><name name-style="western"><surname>K&#246;nig</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fromm</surname><given-names>M. F.</given-names></name><article-title>Inhibitory Effects
of Green Tea and (&#8722;)-Epigallocatechin Gallate on Transport
by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>10</issue><elocation-id>e0139370</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0139370</pub-id><pub-id pub-id-type="pmid">26426900</pub-id><pub-id pub-id-type="pmcid">PMC4591125</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Lilja</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Raaska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>P. J.</given-names></name><article-title>Effects
of Orange Juice on the Pharmacokinetics
of Atenolol</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2005</year><volume>61</volume><issue>5&#8211;6</issue><fpage>337</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1007/s00228-005-0930-9</pub-id><pub-id pub-id-type="pmid">15983823</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Tapaninen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Niemi</surname><given-names>M.</given-names></name><article-title>Orange and Apple Juice
Greatly Reduce
the Plasma Concentrations of the OATP2B1 Substrate Aliskiren</article-title><source>Br. J. Clin. Pharmacol.</source><year>2011</year><volume>71</volume><issue>5</issue><fpage>718</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2010.03898.x</pub-id><pub-id pub-id-type="pmid">21204914</pub-id><pub-id pub-id-type="pmcid">PMC3093077</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Dresser</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Leake</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>U. I.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R. B.</given-names></name><article-title>Fruit Juices
Inhibit Organic Anion
Transporting Polypeptide-Mediated Drug Uptake to Decrease the Oral
Availability of Fexofenadine</article-title><source>Clin. Pharmacol.
Ther.</source><year>2002</year><volume>71</volume><issue>1</issue><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1067/mcp.2002.121152</pub-id><pub-id pub-id-type="pmid">11823753</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Satoh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tsujimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koyabu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ohtani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>Y.</given-names></name><article-title>Citrus Juices Inhibit the Function
of Human Organic Anion-Transporting Polypeptide OATP-B</article-title><source>Drug Metab. Dispos. Biol. Fate Chem.</source><year>2005</year><volume>33</volume><issue>4</issue><fpage>518</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.002337</pub-id><pub-id pub-id-type="pmid">15640378</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Hubatsch</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ragnarsson</surname><given-names>E. G. E.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name><article-title>Determination of Drug Permeability
and Prediction of Drug Absorption in Caco-2 Monolayers</article-title><source>Nat. Protoc.</source><year>2007</year><volume>2</volume><issue>9</issue><fpage>2111</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.303</pub-id><pub-id pub-id-type="pmid">17853866</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Kusuhara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Furuie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Inano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sunagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fukizawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sumita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mayahara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y.</given-names></name><article-title>Pharmacokinetic Interaction Study of Sulphasalazine
in Healthy Subjects and the Impact of Curcumin as an in Vivo Inhibitor
of BCRP</article-title><source>Br. J. Pharmacol.</source><year>2012</year><volume>166</volume><issue>6</issue><fpage>1793</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.01887.x</pub-id><pub-id pub-id-type="pmid">22300367</pub-id><pub-id pub-id-type="pmcid">PMC3402804</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>S&#225;f&#225;r</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kecskem&#233;ti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moln&#225;r</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurunczi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szab&#243;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jan&#225;ky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Krajcsi</surname><given-names>P.</given-names></name><article-title>Inhibition of ABCG2/BCRP-Mediated
Transport-Correlation Analysis of Various Expression Systems and Probe
Substrates</article-title><source>Eur. J. Pharm. Sci.</source><year>2021</year><volume>156</volume><elocation-id>105593</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105593</pub-id><pub-id pub-id-type="pmid">33059043</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Sj&#246;stedt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Holvikari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tammela</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kidron</surname><given-names>H.</given-names></name><article-title>Inhibition of Breast
Cancer Resistance Protein and Multidrug Resistance Associated Protein
2 by Natural Compounds and Their Derivatives</article-title><source>Mol. Pharmaceutics</source><year>2017</year><volume>14</volume><issue>1</issue><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00754</pub-id><pub-id pub-id-type="pmid">28043125</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Eid</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>El-Readi</surname><given-names>M. Z.</given-names></name><name name-style="western"><surname>Wink</surname><given-names>M.</given-names></name><article-title>Carotenoids
Reverse Multidrug Resistance
in Cancer Cells by Interfering with ABC-Transporters</article-title><source>Phytomedicine</source><year>2012</year><volume>19</volume><issue>11</issue><fpage>977</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2012.05.010</pub-id><pub-id pub-id-type="pmid">22770743</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Teng</surname><given-names>Y.-N.</given-names></name><name name-style="western"><surname>Sheu</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.-Y.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.-C.</given-names></name><article-title>&#946;-Carotene
Reverses Multidrug Resistant Cancer
Cells by Selectively Modulating Human P-Glycoprotein Function</article-title><source>Phytomedicine</source><year>2016</year><volume>23</volume><issue>3</issue><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2016.01.008</pub-id><pub-id pub-id-type="pmid">26969385</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Kitagawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nabekura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kamiyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kashiwada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ikeshiro</surname><given-names>Y.</given-names></name><article-title>Effects of Alkyl Gallates
on P-Glycoprotein Function</article-title><source>Biochem. Pharmacol.</source><year>2005</year><volume>70</volume><issue>8</issue><fpage>1262</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2005.07.013</pub-id><pub-id pub-id-type="pmid">16139251</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Beltr&#225;n-de-Miguel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Est&#233;vez-Santiago</surname><given-names>R.</given-names></name><name name-style="western"><surname>Olmedilla-Alonso</surname><given-names>B.</given-names></name><article-title>Assessment
of Dietary Vitamin A Intake (Retinol, &#945;-Carotene, &#946;-Carotene,
&#946;-Cryptoxanthin) and Its Sources in the National Survey of Dietary
Intake in Spain (2009&#8211;2010)</article-title><source>Int. J.
Food Sci. Nutr.</source><year>2015</year><volume>66</volume><issue>6</issue><fpage>706</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.3109/09637486.2015.1077787</pub-id><pub-id pub-id-type="pmid">26313699</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Curran-Celentano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Ciulla</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Danis</surname><given-names>R. B.</given-names></name><article-title>Relation between Dietary Intake,
Serum Concentrations,
and Retinal Concentrations of Lutein and Zeaxanthin in Adults in a
Midwest Population</article-title><source>Am. J. Clin. Nutr.</source><year>2001</year><volume>74</volume><issue>6</issue><fpage>796</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1093/ajcn/74.6.796</pub-id><pub-id pub-id-type="pmid">11722962</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>George</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>F. E.</given-names></name><name name-style="western"><surname>Midthune</surname><given-names>D.</given-names></name><name name-style="western"><surname>Subar</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Berrigan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schatzkin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Potischman</surname><given-names>N.</given-names></name><article-title>Strength of the Relationships between
Three Self-Reported Dietary Intake Instruments and Serum Carotenoids:
The Observing Energy and Protein Nutrition (OPEN) Study</article-title><source>Public Health Nutr.</source><year>2012</year><volume>15</volume><issue>6</issue><fpage>1000</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1017/S1368980011003272</pub-id><pub-id pub-id-type="pmid">22230252</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Lucarini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lanzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#8217;Evoli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lombardi-Boccia</surname><given-names>G.</given-names></name><article-title>Intake of
Vitamin A and Carotenoids from the Italian Population &#8211; Results
of an Italian Total Diet Study</article-title><source>Int. J. Vitam.
Nutr. Res.</source><year>2006</year><volume>76</volume><issue>3</issue><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1024/0300-9831.76.3.103</pub-id><pub-id pub-id-type="pmid">17048188</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>O&#8217;Neill</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Corridan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Olmedilla</surname><given-names>B.</given-names></name><name name-style="western"><surname>Granado</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>I.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>H. V. D.</given-names></name><name name-style="western"><surname>Hininger</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rousell</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Southon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thurnham</surname><given-names>D. I.</given-names></name><article-title>A European
Carotenoid Database to Assess Carotenoid Intakes and Its Use in a
Five-Country Comparative Study</article-title><source>Br. J. Nutr.</source><year>2001</year><volume>85</volume><issue>4</issue><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1079/BJN2000284</pub-id><pub-id pub-id-type="pmid">11348565</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Dixit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Purshottam</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Das</surname><given-names>M.</given-names></name><article-title>Usage Pattern
and Exposure Assessment of Food Colours in Different Age Groups of
Consumers in the State of Uttar Pradesh</article-title><source>India.
Food Addit. Contam. Part A</source><year>2010</year><volume>27</volume><issue>2</issue><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1080/19440040903268062</pub-id><pub-id pub-id-type="pmid">19890754</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Husain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sawaya</surname><given-names>W.</given-names></name><name name-style="western"><surname>Al-Omair</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Zenki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al-Amiri</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Al-Sinan</surname><given-names>M.</given-names></name><article-title>Estimates
of Dietary Exposure of
Children to Artificial Food Colours in Kuwait</article-title><source>Food Addit. Contam.</source><year>2006</year><volume>23</volume><issue>3</issue><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1080/02652030500429125</pub-id><pub-id pub-id-type="pmid">16517526</pub-id></element-citation></ref><ref id="ref56"><mixed-citation publication-type="book" id="cit56"><source>Regulation (EC) 2018/1481. Comission Regulation (EU) 2018/1481
of
4 October 2018 Amending Annexes II and III to Regulation (EC) No 1333/2008
of the European Parliament and of the Council and the Annex to Commission
Regulation (EU) No 231/2012 as Regards Octyl Gallate (E 311) and Dodecyl
Gallate (E 312)</source>;&amp;nbsp;<publisher-name>European Union</publisher-name><year>2018</year>.</mixed-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Palm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Luthman</surname><given-names>K.</given-names></name><article-title>Caco-2 Monolayers in Experimental
and Theoretical Predictions of Drug Transport1</article-title><source>Adv. Drug Delivery Rev.</source><year>2001</year><volume>46</volume><issue>1</issue><fpage>27</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(00)00128-9</pub-id><pub-id pub-id-type="pmid">11259831</pub-id></element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Hidalgo</surname><given-names>I. J.</given-names></name><name name-style="western"><surname>Raub</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Borchardt</surname><given-names>R. T.</given-names></name><article-title>Characterization
of the Human Colon
Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial
Permeability</article-title><source>Gastroenterology</source><year>1989</year><volume>96</volume><issue>2</issue><fpage>736</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(89)80072-1</pub-id><pub-id pub-id-type="pmid">2914637</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Br&#252;ck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Strohmeier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Busch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Drozdzik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oswald</surname><given-names>S.</given-names></name><article-title>Caco-2 Cells
&#8211; Expression, Regulation and Function of Drug Transporters
Compared with Human Jejunal Tissue</article-title><source>Biopharm.
Drug Dispos.</source><year>2017</year><volume>38</volume><issue>2</issue><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1002/bdd.2025</pub-id><pub-id pub-id-type="pmid">27516347</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>&#214;lander</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wi&#347;niewski</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Matsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lundquist</surname><given-names>P.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name><article-title>The Proteome of Filter-Grown Caco-2 Cells With a Focus
on Proteins Involved in Drug Disposition</article-title><source>J.
Pharm. Sci.</source><year>2016</year><volume>105</volume><issue>2</issue><fpage>817</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2015.10.030</pub-id><pub-id pub-id-type="pmid">26869432</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Uchida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamiie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ohmine</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwase</surname><given-names>R.</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>T.</given-names></name><article-title>Quantitative Targeted Absolute Proteomics
for 28 Human
Transporters in Plasma Membrane of Caco-2 Cell Monolayer Cultured
for 2, 3, and 4 Weeks</article-title><source>Drug Metab. Pharmacokinet.</source><year>2015</year><volume>30</volume><issue>2</issue><fpage>205</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.dmpk.2014.11.002</pub-id><pub-id pub-id-type="pmid">25770030</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Belliard</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Lacour</surname><given-names>B.</given-names></name><name name-style="western"><surname>Farinotti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>C.</given-names></name><article-title>Effect of Tumor Necrosis
Factor-&#945; and Interferon-&#947; on Intestinal P-Glycoprotein
Expression, Activity, and Localization in Caco-2 Cells</article-title><source>J. Pharm. Sci.</source><year>2004</year><volume>93</volume><issue>6</issue><fpage>1524</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1002/jps.20072</pub-id><pub-id pub-id-type="pmid">15124210</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Tocchetti</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Arias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arana</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Rigalli</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Dom&#237;nguez</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Zecchinati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>S. S. M.</given-names></name><name name-style="western"><surname>Mottino</surname><given-names>A. D.</given-names></name><article-title>Acute Regulation
of Multidrug Resistance-Associated
Protein 2 Localization and Activity by cAMP and Estradiol-17&#946;-d-Glucuronide
in Rat Intestine and Caco-2 Cells</article-title><source>Arch. Toxicol.</source><year>2018</year><volume>92</volume><issue>2</issue><fpage>777</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1007/s00204-017-2092-9</pub-id><pub-id pub-id-type="pmid">29052767</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Xia</surname><given-names>C. Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Miwa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L.-S.</given-names></name><article-title>Expression, Localization,
and Functional Characteristics of Breast Cancer Resistance Protein
in Caco-2 Cells</article-title><source>Drug Metab. Dispos.</source><year>2005</year><volume>33</volume><issue>5</issue><fpage>637</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.003442</pub-id><pub-id pub-id-type="pmid">15716365</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Keiser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaltheuner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wildberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grube</surname><given-names>M.</given-names></name><name name-style="western"><surname>Partecke</surname><given-names>L. I.</given-names></name><name name-style="western"><surname>Heidecke</surname><given-names>C.-D.</given-names></name><name name-style="western"><surname>Oswald</surname><given-names>S.</given-names></name><article-title>The Organic
Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane
of the Human Jejunum and Caco-2 Monolayers</article-title><source>J. Pharm. Sci.</source><year>2017</year><volume>106</volume><issue>9</issue><fpage>2657</fpage><lpage>2663</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.04.001</pub-id><pub-id pub-id-type="pmid">28408210</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Sai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitsuoka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tamai</surname><given-names>I.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>A.</given-names></name><article-title>Predominant Contribution
of Organic Anion Transporting Polypeptide OATP-B (OATP2B1) to Apical
Uptake of Estrone-3-Sulfate by Human Intestinal Caco-2 Cells</article-title><source>Drug Metab. Dispos. Biol. Fate Chem.</source><year>2006</year><volume>34</volume><issue>8</issue><fpage>1423</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1124/dmd.106.009530</pub-id><pub-id pub-id-type="pmid">16714376</pub-id></element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Kawahara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kono</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>T.</given-names></name><article-title>The Impact
of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport
Across Caco-2 Cell Monolayers</article-title><source>Drug Metab. Dispos.</source><year>2020</year><volume>48</volume><issue>6</issue><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1124/dmd.119.088674</pub-id><pub-id pub-id-type="pmid">32193356</pub-id></element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Yamasaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kusuhara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tabuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ando</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ware</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y.</given-names></name><article-title>Pharmacogenetic Characterization
of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms
in Humans</article-title><source>Clin. Pharmacol. Ther.</source><year>2008</year><volume>84</volume><issue>1</issue><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100459</pub-id><pub-id pub-id-type="pmid">18167504</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Jacqueroux</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hodin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saib</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Del&#233;zay</surname><given-names>O.</given-names></name><name name-style="western"><surname>Delavenne</surname><given-names>X.</given-names></name><article-title>Value of Quantifying
ABC Transporters
by Mass Spectrometry and Impact on <italic toggle="yes">in Vitro</italic>-to-<italic toggle="yes">in Vivo</italic> Prediction of Transporter-Mediated Drug-Drug Interactions
of Rivaroxaban</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2020</year><volume>148</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2020.01.002</pub-id><pub-id pub-id-type="pmid">31945490</pub-id></element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Karlgren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vildhede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Norinder</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Kimoto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Haglund</surname><given-names>U.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name><article-title>Classification
of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs):
Influence of Protein Expression on Drug-Drug Interactions</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><issue>10</issue><fpage>4740</fpage><lpage>4763</lpage><pub-id pub-id-type="doi">10.1021/jm300212s</pub-id><pub-id pub-id-type="pmid">22541068</pub-id><pub-id pub-id-type="pmcid">PMC3361267</pub-id></element-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Matsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Norinder</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>C. A. S.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name><article-title>Identification
of Novel Specific and General Inhibitors
of the Three Major Human ATP-Binding Cassette Transporters P-Gp, BCRP
and MRP2 Among Registered Drugs</article-title><source>Pharm. Res.</source><year>2009</year><volume>26</volume><issue>8</issue><fpage>1816</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9896-0</pub-id><pub-id pub-id-type="pmid">19421845</pub-id></element-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><person-group person-group-type="allauthors"><collab>EFSA</collab></person-group><article-title>European Union</article-title>. <source>EFSA J.</source><year>2010</year>, <volume>8</volume><issue>11</issue>.</mixed-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><collab>EFSA</collab><article-title>Scientific Opinion on the Re-Evaluation
Tartrazine (E 102)</article-title><source>EFSA J.</source><year>2009</year><volume>7</volume><issue>11</issue><fpage>1331</fpage><pub-id pub-id-type="doi">10.2903/j.efsa.2009.1331</pub-id></element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><collab>EFSA</collab><article-title>Scientific Opinion
on the Re-Evaluation
of Sunset Yellow FCF (E 110) as a Food Additive</article-title><source>EFSA J.</source><year>2009</year><volume>7</volume><issue>11</issue><fpage>1330</fpage><pub-id pub-id-type="doi">10.2903/j.efsa.2009.1330</pub-id></element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><collab>EFSA</collab><article-title>Scientific Opinion on the Re-Evaluation
of Azorubine/Carmoisine (E 122) as a Food Additive</article-title><source>EFSA J.</source><year>2009</year><volume>7</volume><issue>11</issue><fpage>1332</fpage><pub-id pub-id-type="doi">10.2903/j.efsa.2009.1332</pub-id></element-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><collab>EFSA</collab><article-title>Scientific Opinion on the Re-Evaluation
of Allura Red AC (E 129) as a Food Additive</article-title><source>EFSA J.</source><year>2009</year><volume>7</volume><issue>11</issue><fpage>1327</fpage><pub-id pub-id-type="doi">10.2903/j.efsa.2009.1327</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Kruger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Venturelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>J.</given-names></name><article-title>Low &#946;-Carotene Bioaccessibility and Bioavailability from High
Fat</article-title><source>Dairy-Based Meal. Eur. J. Nutr.</source><year>2024</year><volume>63</volume><issue>6</issue><fpage>2261</fpage><lpage>2270</lpage><pub-id pub-id-type="doi">10.1007/s00394-024-03423-w</pub-id><pub-id pub-id-type="pmid">38753174</pub-id><pub-id pub-id-type="pmcid">PMC11377643</pub-id></element-citation></ref><ref id="ref78"><element-citation publication-type="journal" id="cit78"><name name-style="western"><surname>Sy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gleize</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dangles</surname><given-names>O.</given-names></name><name name-style="western"><surname>Landrier</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Veyrat</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Borel</surname><given-names>P.</given-names></name><article-title>Effects of
Physicochemical Properties of Carotenoids on Their Bioaccessibility,
Intestinal Cell Uptake, and Blood and Tissue Concentrations</article-title><source>Mol. Nutr. Food Res.</source><year>2012</year><volume>56</volume><issue>9</issue><fpage>1385</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201200041</pub-id><pub-id pub-id-type="pmid">22815251</pub-id></element-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><article-title>Study of Structure
and Permeability Relationship of Flavonoids in Caco-2 Cells</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><issue>12</issue><fpage>1301</fpage><pub-id pub-id-type="doi">10.3390/nu9121301</pub-id><pub-id pub-id-type="pmid">29186068</pub-id><pub-id pub-id-type="pmcid">PMC5748751</pub-id></element-citation></ref><ref id="ref80"><element-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jianshe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><article-title>Application
of a Liquid Chromatography-Tandem Mass Spectrometry Method to the
Pharmacokinetics, Bioavailability and Tissue Distribution of Neohesperidin
Dihydrochalcone in Rats</article-title><source>Xenobiotica</source><year>2014</year><volume>44</volume><issue>6</issue><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.3109/00498254.2013.861950</pub-id><pub-id pub-id-type="pmid">24274324</pub-id></element-citation></ref><ref id="ref81"><element-citation publication-type="journal" id="cit81"><name name-style="western"><surname>McGovern</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Helfand</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>A Specific Mechanism
of Nonspecific Inhibition</article-title><source>J. Med. Chem.</source><year>2003</year><volume>46</volume><issue>20</issue><fpage>4265</fpage><lpage>4272</lpage><pub-id pub-id-type="doi">10.1021/jm030266r</pub-id><pub-id pub-id-type="pmid">13678405</pub-id></element-citation></ref><ref id="ref82"><element-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Nozaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>S.</given-names></name><article-title>Preincubation Time-Dependent,
Long-Lasting Inhibition of Drug Transporters
and Impact on the Prediction of Drug&#8211;Drug Interactions</article-title><source>Drug Metab. Dispos.</source><year>2023</year><volume>51</volume><issue>9</issue><fpage>1077</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1124/dmd.122.000970</pub-id><pub-id pub-id-type="pmid">36854606</pub-id></element-citation></ref><ref id="ref83"><element-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Sinokki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miinalainen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kiander</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kidron</surname><given-names>H.</given-names></name><article-title>Preincubation-Dependent
Inhibition of Organic Anion Transporting Polypeptide 2B1</article-title><source>Eur. J. Pharm. Sci.</source><year>2024</year><volume>200</volume><elocation-id>106852</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejps.2024.106852</pub-id><pub-id pub-id-type="pmid">39019347</pub-id></element-citation></ref><ref id="ref84"><element-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Izumi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nozaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y.</given-names></name><article-title>Experimental
and Modeling
Evidence Supporting the Trans-Inhibition Mechanism for Preincubation
Time-Dependent, Long-Lasting Inhibition of Organic Anion Transporting
Polypeptide 1B1 by Cyclosporine AS</article-title><source>Drug Metab.
Dispos.</source><year>2022</year><volume>50</volume><issue>5</issue><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1124/dmd.121.000783</pub-id><pub-id pub-id-type="pmid">35241487</pub-id></element-citation></ref><ref id="ref85"><element-citation publication-type="journal" id="cit85"><name name-style="western"><surname>T&#225;trai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Temesszentandr&#225;si-Ambrus</surname><given-names>C.</given-names></name><name name-style="western"><surname>Varga</surname><given-names>T.</given-names></name><name name-style="western"><surname>G&#225;borik</surname><given-names>Z.</given-names></name><article-title>The Inhibitor
Preincubation Effect Is Universal to SLC Transporter Assays and Is
Only Partially Eliminated in the Presence of Extracellular Protein</article-title><source>Drug Metab. Dispos.</source><year>2023</year><volume>51</volume><issue>8</issue><fpage>982</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1124/dmd.122.001191</pub-id><pub-id pub-id-type="pmid">37208186</pub-id></element-citation></ref><ref id="ref86"><element-citation publication-type="journal" id="cit86"><name name-style="western"><surname>Braune</surname><given-names>A.</given-names></name><name name-style="western"><surname>Engst</surname><given-names>W.</given-names></name><name name-style="western"><surname>Blaut</surname><given-names>M.</given-names></name><article-title>Degradation
of Neohesperidin Dihydrochalcone
by Human Intestinal Bacteria</article-title><source>J. Agric. Food
Chem.</source><year>2005</year><volume>53</volume><issue>5</issue><fpage>1782</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1021/jf0484982</pub-id><pub-id pub-id-type="pmid">15740074</pub-id></element-citation></ref><ref id="ref87"><element-citation publication-type="journal" id="cit87"><name name-style="western"><surname>Chung</surname><given-names>K.-T.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Cerniglia</surname><given-names>C. E.</given-names></name><article-title>The Reduction of Azo Dyes by the
Intestinal Microflora</article-title><source>Crit. Rev. Microbiol.</source><year>1992</year><volume>18</volume><issue>3</issue><fpage>175</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.3109/10408419209114557</pub-id><pub-id pub-id-type="pmid">1554423</pub-id></element-citation></ref><ref id="ref88"><element-citation publication-type="journal" id="cit88"><name name-style="western"><surname>Gardana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simonetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Canzi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zanchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pietta</surname><given-names>P.</given-names></name><article-title>Metabolism
of Stevioside and Rebaudioside A from Stevia Rebaudiana Extracts by
Human Microflora</article-title><source>J. Agric. Food Chem.</source><year>2003</year><volume>51</volume><issue>22</issue><fpage>6618</fpage><lpage>6622</lpage><pub-id pub-id-type="doi">10.1021/jf0303619</pub-id><pub-id pub-id-type="pmid">14558786</pub-id></element-citation></ref><ref id="ref89"><element-citation publication-type="journal" id="cit89"><name name-style="western"><surname>Chan</surname><given-names>L. M.
S.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirst</surname><given-names>B. H.</given-names></name><article-title>The ABCs of Drug Transport in Intestine
and Liver: Efflux Proteins Limiting Drug Absorption and Bioavailability</article-title><source>Eur. J. Pharm. Sci.</source><year>2004</year><volume>21</volume><issue>1</issue><fpage>25</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2003.07.003</pub-id><pub-id pub-id-type="pmid">14706810</pub-id></element-citation></ref><ref id="ref90"><element-citation publication-type="journal" id="cit90"><name name-style="western"><surname>Takano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yumoto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T.</given-names></name><article-title>Expression
and Function of Efflux
Drug Transporters in the Intestine</article-title><source>Pharmacol.
Ther.</source><year>2006</year><volume>109</volume><issue>1&#8211;2</issue><fpage>137</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2005.06.005</pub-id><pub-id pub-id-type="pmid">16209890</pub-id></element-citation></ref><ref id="ref91"><element-citation publication-type="journal" id="cit91"><name name-style="western"><surname>Nosol</surname><given-names>K.</given-names></name><name name-style="western"><surname>Romane</surname><given-names>K.</given-names></name><name name-style="western"><surname>Irobalieva</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Locher</surname><given-names>K. P.</given-names></name><article-title>Cryo-EM
Structures Reveal Distinct
Mechanisms of Inhibition of the Human Multidrug Transporter ABCB1</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2020</year><volume>117</volume><issue>42</issue><fpage>26245</fpage><lpage>26253</lpage><pub-id pub-id-type="doi">10.1073/pnas.2010264117</pub-id><pub-id pub-id-type="pmid">33020312</pub-id><pub-id pub-id-type="pmcid">PMC7585025</pub-id></element-citation></ref><ref id="ref92"><element-citation publication-type="journal" id="cit92"><name name-style="western"><surname>Aller</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chittaboina</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harrell</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>Y. T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Urbatsch</surname><given-names>I. L.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G.</given-names></name><article-title>Structure
of P-Glycoprotein Reveals
a Molecular Basis for Poly-Specific Drug Binding</article-title><source>Science</source><year>2009</year><volume>323</volume><issue>5922</issue><fpage>1718</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1126/science.1168750</pub-id><pub-id pub-id-type="pmid">19325113</pub-id><pub-id pub-id-type="pmcid">PMC2720052</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>